Where Will Centrus Energy (LEU) Stock Be in 1 Year?

Centrus Energy (NYSE: LEU) shares have nearly quadrupled over the past 12 months as uranium spot prices recovered to $81.55/lb (end-2025) and HALEU production for government contracts ramped, helping revenue grow at a 15% CAGR from 2018–2024 to $442 million. Analysts model a more modest 7% revenue CAGR to $538 million by 2027 (EPS CAGR ~2%), but the stock trades at a premium (~$286/sh, $5.2 billion market cap, ~72x earnings and 11x sales), leaving limited near-term upside absent stronger near-term catalysts or faster HALEU commercialization.

Analysis

Market structure: Centrus (LEU) is the near-term winner from HALEU pilot contracts and long-term SWU contracts, while commodity-exposed miners (e.g., CCJ) benefit if spot uranium rises; exporters reliant on Russian supply are losers if geopolitical flows stay restricted. Centrus’ unique HALEU tech gives pricing power on a small addressable base today, but its core LEU reseller business remains tightly linked to uranium spot and SWU pricing—creating asymmetric upside vs. downside given a 72x P/E and 11x sales multiple at $286/share.

Risk assessment: Tail risks include a rapid restoration of Russian/Rosatom supply (price shock), a DOE/contracting setback or an operational failure at Centrus’ enrichment facilities, each capable of >30% equity moves. Timeline: expect high volatility in days–weeks around quarterly results and DOE/contract announcements, 3–12 months for uranium spot to test $100, and 2–5 years for HALEU adoption to materially lift revenues beyond the 7% CAGR to 2027.

Trade implications: Favor relative-value exposure to physical levered plays—long miners (CCJ) and short premium equities (LEU). Use options to manage skew: buy LEU 9–12m put spreads to limit cost, and buy CCJ 12m call LEAPS or 6–12m call spreads to capture a >25% uranium rally. Size tactical exposure small (2–4% portfolio) until catalysts confirm supply tightness.

Contrarian angles: The market underestimates the difficulty/timing of HALEU scale-up—21.9% CAGR to 2033 is consensus but faces licensing and capex slippage, so much growth may be back-loaded. The 2025 rerating resembles 2007 uranium euphoria; if miners ramp, supply could blunt prices and expose LEU’s rich valuation to a mean-reversion >40%.

Key Decisions for Investors

• Establish a small tactical short on LEU: buy a 9–12 month put spread (buy LEU $240 put / sell LEU $160 put) sizing ~2% of portfolio to hedge valuation reversion risk; unwind if LEU P/E compresses to <40x or uranium spot >$120.
• Initiate a 3–4% long position in Cameco (CCJ) via 12-month call spread (buy $30 / sell $45) or outright equity if available; thesis: cleaner leverage to uranium spot which consensus sees rising to $100 in 2026 and $140 in 2027.
• Run a dollar-neutral pair trade: short LEU equal dollar to long CCJ (ratio determined by beta-to-uranium) sized 1–2% net exposure to capture relative re-rating; set stop-loss at 20% adverse move and take-profit at 30% move in favor.
• If already long LEU, sell 3-month covered calls 10% OTM or buy 6–12 month protective puts (threshold: protect below $220) and trim position if LEU >$350 or uranium spot fails to breach $100 within 6 months.
• Monitor these catalysts on a 30–90 day cadence: DOE HALEU contract awards, Centrus quarterly HALEU production updates, and uranium spot crossing $100 (action: add longs to miners if breached; widen LEU shorts if not).